drug · small molecule
cefiderocol sulfate tosylate
Marketedupdated 3mo agoby $SGIOF SHIONOGI & CO LTD🔗 ChEMBL
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for 3 indications.
targets
Bacterial penicillin-binding protein
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Nov 14, 2029
~3.3 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (3)
- Sep 3, 2035compositionUS 10004750
- Sep 3, 2035formulationUS 9949982
- Nov 14, 2033compositionUS 9238657
FDA exclusivities (2)
- Nov 14, 2029GAINGAIN Antibiotic (5y)3.3y
- Nov 14, 2024NCENew Chemical Entity (5y)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that